Abstracts tagged "antiphospholipid antibodies and antiphospholipid syndrome"

Abstract Number: 161 • 2018 ACR/ARHP Annual Meeting
Clinical and Laboratory Characteristics of Persistently Antiphospholipid Antibody Positive Patients: Retrospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Ecem Sevim¹, Diane F. Zisa², Danieli Andrade³, Vittorio Pengo⁴, Maria Tektonidou⁵, Amaia Ugarte⁶, Maria Gerosa⁷, Lanlan Ji⁸, Maria Efthymiou⁹, Guilherme Ramires de Jesus¹⁰, David Branch¹¹, Cecilia Nalli¹², Savino Sciascia¹³, H. Michael Belmont¹⁴, Paul R. Fortin¹⁵, Michelle Petri¹⁶, Esther Rodriguez-Almaraz¹⁷, Rosana Quintana¹⁸, Jason S Knight¹⁹, Rohan Willis²⁰, Tatsuya Atsumi²¹, Maria Laura Bertolaccini²², Doruk Erkan²³ and Medha Barbhaiya²⁴, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Department of Medicine, Weill Cornell Medicine, New York, NY, USA., New York, NY, ³Rheumatology, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁴Azienda Ospedaliera of Padova, University of Padova, Padova, Italy, ⁵Rheumatology Unit, 1st Dept. of Propaedeutic Internal Medicine, Joint Academic Rheumatology Program, Athens University Medical School, Athens, Greece, ⁶Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Biscay, Spain, ⁷Istituto Ortopedico Gaetano Pini, University of Milan, Milano, Italy, ⁸Rheumatology and Immunology, Peking University First Hospital, Beijing, China., Beijing, China, ⁹Haemostasis Research Unit, Department of Haematology, University College London, London, United Kingdom, ¹⁰Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ¹¹Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City, UT, ¹²Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ¹³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, ¹⁴Medicine, NYU Langone Health, New York, NY, ¹⁵Medicine, CHU de Québec - University of Laval, Quebec, QC, Canada, ¹⁶Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁷Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁸Argentina, GLADEL, Rosario, Argentina, ¹⁹University of Michigan, Ann Arbor, MI, ²⁰301 University Blvd, Antiphospholipid Standardization Laboratory, University of Texas Medical Branch, Galveston, TX, USA, Galveston, TX, ²¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ²²King's College London, London, United Kingdom, ²³Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, ²⁴Rheumatology, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: APS ACTION Registry was created to study long-term outcomes in persistently antiphospholipid antibody (aPL)-positive patients with/without other systemic autoimmune diseases (SAIDx). The primary objective…
Abstract Number: 1074 • 2016 ACR/ARHP Annual Meeting
The Risk of Obstetric Complications and the Effects of Treatment in Women with Low Titer and Medium-High Titer Anti-Phospholipid Antibodies
Cecilia B. Chighizola¹, Maria Gabriella Raimondo², Chiara Comerio³, Francesca Pregnolato⁴, Cristina Sobrino⁵, Laura Trespidi⁶, Barbara Acaia⁶, Maria Gerosa⁷, Wally Ossola⁶ and Pier Luigi Meroni⁸, ¹Department of Clinical Sciences and Community Health, University of Milan, IRCCS Istituto Auxologico Italiano, Milano, Italy, ²University of Milan, Istituto Ortopedico Gaetano Pini, Milan, Italy, ³University of Milan, Milan, Italy, ⁴IRCCS Istituto Auxologico Italiano, Milano, Italy, ⁵Istituto Ortopedico Gaetano Pini, Milan, Italy, ⁶Department of Obstetrics and Gynaecology, Fondazione Policlinico, Mangiagalli e Regina Elena, Milan, Italy, ⁷University of Milan, Istituto Ortopedico Gaetano Pini, Milano, Italy, ⁸Rheumatology Department, University of Milan, Istituto Ortopedico Gaetano Pini, Milano, Italy
Background/Purpose: The association of low titer anti-phospholipid antibodies (aPL) with obstetric anti-phospholipid syndrome (APS) is increasingly acknowledged, even though some studies have showed conflicting results.…
Abstract Number: 1964 • 2016 ACR/ARHP Annual Meeting
The Frequency and Clinical Significance of IgA Anticardiolipin and Anti-β2-Glycoprotein-I Antibodies in Antiphospholipid Antibody Patients with and without Lupus
Ayten Yazici^1,2, OZAN UNLU³, Cecilia B. Chighizola⁴, Doruk Erkan⁵, Michelle Petri⁶ and On Behalf of APS ACTION .⁷, ¹Hospital for Special Surgery, Cornell Weill Cornell Medicine, NEW YORK CITY, NY, Turkey, ²Rheumatology, Kocaeli University School of Medicine, Kocaeli, Turkey, ³Rheumatology Department, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴Department of Clinical Sciences and Community Health, University of Milan, IRCCS Istituto Auxologico Italiano, Milano, Italy, ⁵Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, ⁶Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ⁷., New York, NY
Background/Purpose: APS ACTION International Clinical Database and Repository was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive…
Abstract Number: 1966 • 2016 ACR/ARHP Annual Meeting
Antibodies Against Domain 1 and Domain 4/5 of β2 Glycoprotein I: Clinical Relevance in Obstetric Anti-Phospholipid Syndrome
Cecilia B. Chighizola¹, Laura Andreoli^2,3, Marta Tonello⁴, Maria Gabriella Raimondo⁵, Francesca Pregnolato⁶, Cecilia Nalli⁷, Elena Mattia⁸, Laura Cesana⁹, Rajesh Kumar⁷, Chiara Comerio¹⁰, Claudia Grossi⁹, Francesco Mombelli¹¹, Maria Gerosa¹², Maria Orietta Borghi¹³, Amelia Ruffatti¹⁴, Angela Tincani¹⁵ and Pier Luigi Meroni¹⁶, ¹Department of Clinical Sciences and Community Health, University of Milan, IRCCS Istituto Auxologico Italiano, Milano, Italy, ²Rheumatology & Clinical Immunology, University of Brescia/Spedali Civili, Brescia, Italy, ³University of Brescia, Spedali Civili, Brescia, Italy, ⁴Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy, ⁵University of Milan, Istituto Ortopedico Gaetano Pini, Milan, Italy, ⁶IRCCS Istituto Auxologico Italiano, Milano, Italy, ⁷Spedali Civili, Brescia, Italy, ⁸Azienda Ospedaliera of Padova, Padua, Italy, ⁹IRCCS Istituto Auxologico Italiano, Milan, Italy, ¹⁰University of Milan, Milan, Italy, ¹¹University of Brescia, Brescia, Italy, ¹²University of Milan, Istituto Ortopedico Gaetano Pini, Milano, Italy, ¹³University of Milan, IRCCS Istituto Auxologico Italiano, Milan, Italy, ¹⁴Azienda Ospedaliera of Padova, University of Padova, Padova, Italy, ¹⁵Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ¹⁶Rheumatology Department, University of Milan, Istituto Ortopedico Gaetano Pini, Milano, Italy
Background/Purpose: The domain reactivity of antibodies against b2 glycoprotein I (anti-b2GPI) has been investigated in patients with thrombotic anti-phospholipid syndrome (APS), leading to the identification…
Abstract Number: 2102 • 2016 ACR/ARHP Annual Meeting
the Prevalence and Associations of IgG/a/M ANTI-β2GPI and ANTI-Domain I Antibodies in an Antiphospholipid Syndrome (APS) Cohort of Patients from Turkey
Bahar Artim-Esen¹, Thomas McDonnell², Charis Pericleous³, Ozlem Pehlivan⁴, Murat Inanc⁵, Ian Giles⁶ and Anisur Rahman², ¹Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ³Imperial College Vascular Sciences, National Heart and Lung Institute, Imperial College Vascular Sciences, National Heart and Lung Institute, London, United Kingdom, ⁴Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul, Turkey, ⁵Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, İstanbul, Turkey, ⁶Centre for Rheumatology, University College London, Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose: Methods: Results: Conclusion: All patients (n=75) Vascular Thrombosis only (n=15) P IgG anti-β2GPI 17% 19% 14% NS IgA anti-β2GPI 36%…
Abstract Number: 2190 • 2015 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Core Laboratory Validation Exercise: Comparison of Enzyme-Linked Immunosorbant Assay (ELISA) and Chemiluminescence Immunoassay (CIA)
Maria Laura Bertolaccini¹, Danieli Andrade², Gabriella Lakos³, Rohan Willis⁴, Vittorio Pengo⁵, Alessandra Banzato⁶, Hannah Cohen⁷, Steven Krilis⁸, Doruk Erkan⁹ and on behalf of APS ACTION, ¹Lupus Unit, Rayne Institute, Lupus Research Unit, The Rayne Institute, King's College London School of Medicine, St Thomas' Hospital, London, United Kingdom, ²Rheumatology, University of São Paulo, São Paulo, Brazil, ³INOVA Diagnostics, Inc., San Diego, CA, ⁴Department of Internal Medicine, Antiphospholipid Standardization Laboratory, Division of Rheumatology, Galveston, TX, ⁵Clinical Cardiology, Department of Cardiac Thoracic and Vascular Sciences, University of Padova, Padova, Italy, ⁶Department of Cardiac Thoracic and Vascular Sciences, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy, ⁷Hematology., University College London, LOndon, United Kingdom, ⁸Immunology, Allergy, and Infectious Diseases, St George Hospital, Kogarah NSW, Australia, ⁹Rheumatology, Barbara Volcker Center for Women and Rheumatic Diseases: Hospital for Special Surgery, New York, NY
Background/Purpose: APS ACTION International Clinical Database and Repository was created to study the natural course of disease over 10 years in persistently aPL-positive patients with/without…
Abstract Number: 6 • 2014 ACR/ARHP Annual Meeting
Performance Evaluation and Clinical Associations of the Aphl ELISA Compared to Criteria Antiphospholipid Immunoassays in Lupus Patients
Yu Zuo^1,2, Rohan Willis³, Emilio Gonzalez⁴, Allan Brasier⁵, Michelle Petri⁶, Elizabeth Papalardo⁷, E Nigel Harris⁸, Hong Fang⁹, Karel De Ceulaer¹⁰, Monica Smikle¹¹, Luis M. Vila¹², John D. Reveille^13,14, Graciela S. Alarcon¹⁵ and Silvia Pierangeli¹⁶, ¹Internal Medicine, University of Texas Medical Branch in Galveston TX, Galveston, TX, ²Division of Rheumatology, UT Southwestern Medical Center, Dallas, TX, ³515 1st St. Apt. 360, UTMB - Galveston, Galveston, TX, ⁴Rheumatology, University of Texas Medical Branch, Galveston, TX, ⁵Internal Medicine, Endocrinology, UTMB-Galveston, Galveston, TX, ⁶Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Louisville APL Diagnostic, seabrook, TX, ⁸Office of the Vice Chancellor, The University of the West Ind, Kingston, Jamaica, ⁹John Hopkins University School of Medicine, Baltimore, MD, ¹⁰Medicine, Medicine, Kingston, Jamaica, ¹¹Microbiology, University of the West Indies, Kgn 7, Jamaica, ¹²Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ¹³Internal Medicine/Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ¹⁴Internal Medicine/Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX, ¹⁵Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹⁶Rheumatolgoy/Dept Int Med, Univ of TX Medical Branch, Galveston, TX
Background/Purpose: Antiphospholipid Syndrome (APS) is characterized by recurrent thrombotic and obstetric manifestations in the presence of ‘criteria' antiphospholipid antibodies (aPL) [anticardiolipin (aCL), anti-β2glycoproteinI (anti-β2GPI )…
Abstract Number: 22 • 2013 ACR/ARHP Annual Meeting
WHAT Is The Prevalence Of NON CRITERIA ANTIPHOSPHOLIPID ANTIBODIES IN Patients With Antiphospholipid Syndrome?
Veronica Rodriguez-Garcia¹, Yiannis Ioannou², D.a. Isenberg³ and Ian Giles⁴, ¹rheumatology, Hospital Regional Universitario Carlos Haya, Malaga, Spain, ²Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ³Centre for Rheumatology Research, University College London, London, United Kingdom, ⁴Centre for Rheumatology, Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose: Increasing interest has focussed upon assays which are not currently included in the Antiphospholipid syndrome (APS) classification criteria to detect antibodies directed against other…
Abstract Number: 13 • 2013 ACR/ARHP Annual Meeting
A MORE Specific Immunoassay For The Diagnosis Of APS
Claudia Grossi¹, Maria Borghi¹, Elizabeth Papalardo², Silvia S. Pierangeli³ and Pier Luigi Meroni⁴, ¹Lab of immunology, IRCCS Istituto Auxologico Italiano, Milano, Italy, ²Louisville APL Diagnostics, Inc, Seabrook, TX, ³Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ⁴Chair and Division of Rheumatology, Gaetano Pini Institute, University of Milan, Milan, Italy
Background/Purpose: Anticardiolipin (aCL) antibody assays are sensitive for the detection of antiphospholipid antibodies (aPL) in patients with the Antiphospholipid syndrome (APS) but are known to…
Abstract Number: 15 • 2013 ACR/ARHP Annual Meeting
Establishment Of Standardized International Units For IgM ANTI-β₂glycoprotein Antibody Measurement
Rohan Willis¹, Claudia Grossi², Maria Borghi², Pier Luigi Meroni³, Gabriella Lakos⁴, Tammy Buckner⁵, Fernando S. Cavalcanti⁶, Maria Crisostomo⁷, Corina Dima⁸, Kerrie Jaskal⁹, Matthias Kast¹⁰, Luis R. Lopez¹¹, Nina Olschowka¹⁰, Sarah Paul¹², Tony Prestigiacomo¹³, Josep Puig⁶, Wendy Vandam¹³, Alfredo Villarreal¹², Roger Walker⁷, Mike Watkins¹² and Silvia S. Pierangeli¹⁴, ¹Int Medicine/Rheumatology, University of Texas Medical Branch, Galveston, TX, ²Lab of immunology, IRCCS Istituto Auxologico Italiano, Milano, Italy, ³Chair and Division of Rheumatology, Gaetano Pini Institute, University of Milan, Milan, Italy, ⁴Research, INOVA Diagnostics, San Diego, CA, ⁵Corgenix, Broomfield, CO, ⁶Biokit, Barcelona, Spain, ⁷Bio-rad Laboriatories, In, Bio-Rad Laboratories, Hercules, CA, ⁸Microbiology, Theratest Laboratories Inc, Lombard, IL, ⁹Instrumentation Laboratories, Bedford, MA, ¹⁰Phadia Thermofisher, Freiburg, MN, Germany, ¹¹Corgenix Inc, Broomfield, CO, ¹²BioPlex Division, Bio-Rad Laboratories, Benicia, CA, ¹³Bio-Rad Laboratories, Hercules, CA, ¹⁴Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX
Background/Purpose: Recurrent IgG or IgM anti-β2glycoprotein (ab2GPI) antibody positivity is a key laboratory indicator for classification of antiphospholipid syndrome (APS). Considerable inter-laboratory variation still exists…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].